In the randomized trial mentioned in the AE37 subsection (NCT00524277) on clinically disease-free breast cancer patients with node-positive or high-risk node-negative disease, GP2 was administered to HLA-A2-positive patients in combination with GM-CSF as a vaccine adjuvant in 6 monthly intradermal inoculations as the primary vaccine series (PVS), followed by booster inoculations every 6 months. Here, CSF2 is linked to breast carcinoma.